-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
450,450 Shares in Sunshine Biopharma, Inc. (NASDAQ:SBFM) Acquired by Empery Asset Management LP
450,450 Shares in Sunshine Biopharma, Inc. (NASDAQ:SBFM) Acquired by Empery Asset Management LP
Empery Asset Management LP purchased a new position in Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 450,450 shares of the company's stock, valued at approximately $1,104,000. Sunshine Biopharma makes up about 5.2% of Empery Asset Management LP's investment portfolio, making the stock its 5th largest holding. Empery Asset Management LP owned 2.73% of Sunshine Biopharma as of its most recent SEC filing.
Sunshine Biopharma Price Performance
NASDAQ SBFM opened at $1.06 on Tuesday. The stock's 50 day moving average is $1.15 and its 200 day moving average is $1.99. Sunshine Biopharma, Inc. has a 12 month low of $1.01 and a 12 month high of $29.80.
Get Sunshine Biopharma alerts:About Sunshine Biopharma
(Get Rating)
Sunshine Biopharma, Inc, a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound.Further Reading
- Get a free copy of the StockNews.com research report on Sunshine Biopharma (SBFM)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
Want to see what other hedge funds are holding SBFM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating).
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
Empery Asset Management LP purchased a new position in Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 450,450 shares of the company's stock, valued at approximately $1,104,000. Sunshine Biopharma makes up about 5.2% of Empery Asset Management LP's investment portfolio, making the stock its 5th largest holding. Empery Asset Management LP owned 2.73% of Sunshine Biopharma as of its most recent SEC filing.
根據Empery Asset Management LP提交給美國證券交易委員會的最新Form 13F文件，該公司在第一季度購買了陽光生物製藥公司(Temasek Holdings：SBFM-GET Rating)的新頭寸。該基金購買了450,450股該公司股票，價值約1,104,000美元。陽光生物在Empery Asset Management LP的投資組合中約佔5.2%，使該股成為其第五大持股。截至最近提交的美國證券交易委員會申請文件，Empery Asset Management LP持有陽光生物科技2.73%的股份。
Sunshine Biopharma Price Performance
陽光生物醫藥價格表現
NASDAQ SBFM opened at $1.06 on Tuesday. The stock's 50 day moving average is $1.15 and its 200 day moving average is $1.99. Sunshine Biopharma, Inc. has a 12 month low of $1.01 and a 12 month high of $29.80.
納斯達克點評週二開盤價為1.06美元。該股的50日移動均線切入位在1.15美元，200日移動均線切入位在1.99美元。陽光生物醫藥公司的股價為1.01美元的12個月低點和29.80美元的12個月高位。
About Sunshine Biopharma
關於陽光生物醫藥
(Get Rating)
(獲取評級)
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Sunshine Biopharma (SBFM)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- 免費獲取StockNews.com關於陽光生物醫學的研究報告(SBFM)
- 這些股息獲得者值得在你的投資組合中佔有一席之地嗎？
- 達頓餐廳走低通脹之路
- 這3只股票為何在9月火爆開盤
- 通貨膨脹沒有差別，但它的影響有差別
- 3只被降級的必備股票放在你的觀察名單上
Want to see what other hedge funds are holding SBFM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating).
想看看其他對衝基金持有SBFM的情況嗎？訪問HoldingsChannel.com獲取陽光生物醫藥公司(納斯達克代碼：SBFM-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《陽光生物報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對陽光生物醫藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧